RS
DAWN

R Squared’s Day One Biopharmaceuticals DAWN Stock Holding History

R Squared’s Portfolio DAWN Stock Details DAWN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-2,450
Closed -$31K – 603
2024
Q4 		$31K Buy
+2,450
New +$34.1K 0.03% 687

Other funds holding DAWN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
ECM
Estuary Capital Management Wayzata, Minnesota $598M AUM 1.72% 1-Year Est. Return

R Squared's DAWN Position: Q1 2025 in Review

R Squared sold out of Day One Biopharmaceuticals (DAWN) in Q1 2025, closing a stake of 2,450 shares — an estimated $31K sold.

R Squared first reported a position in DAWN in Q4 2024 and held it in 1 quarter. The position peaked at $31K in Q4 2024. 184 funds tracked by Wall St. Rank hold DAWN as of Q1 2025.

  • R Squared reported no remaining Day One Biopharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • R Squared sold 2,450 Day One Biopharmaceuticals shares in Q1 2025, an estimated $31K.
  • R Squared first reported a position in Day One Biopharmaceuticals in Q4 2024 and held it in 1 quarter.
  • R Squared's Day One Biopharmaceuticals position peaked at $31K in Q4 2024.
  • 184 funds tracked by Wall St. Rank held Day One Biopharmaceuticals as of Q1 2025.

Based on R Squared's 13F filing for Q1 2025, filed 9 May 2025.